Hortobagyi GN - Search Results

1

Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.

Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC Jr, Hortobagyi GN, Hung MC. Wei Y, et al. Among authors: hortobagyi gn. Mol Carcinog. 2008 Sep;47(9):701-6. doi: 10.1002/mc.20413. Mol Carcinog. 2008. PMID: 18176935 Free PMC article.

2

The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.

Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC. Chang JY, et al. Among authors: hortobagyi gn. Oncogene. 1997 Feb 6;14(5):561-8. doi: 10.1038/sj.onc.1200861. Oncogene. 1997. PMID: 9053854

3

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.

Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Yu D, et al. Among authors: hortobagyi gn. Oncogene. 1998 Apr 23;16(16):2087-94. doi: 10.1038/sj.onc.1201729. Oncogene. 1998. PMID: 9572489

4

Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.

Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C, Hung MC. Zhang L, et al. Among authors: hortobagyi gn. Oncogene. 1998 Jun 4;16(22):2855-63. doi: 10.1038/sj.onc.1201813. Oncogene. 1998. PMID: 9671406

5

A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer.

Hortobagyi GN, Hung MC, Lopez-Berestein G. Hortobagyi GN, et al. Hum Gene Ther. 1998 Aug 10;9(12):1775-98. doi: 10.1089/hum.1998.9.12-1775. Hum Gene Ther. 1998. PMID: 9721088 Clinical Trial. No abstract available.

6

Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.

Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. Zhang L, et al. Among authors: hortobagyi gn. Clin Cancer Res. 1999 Feb;5(2):343-53. Clin Cancer Res. 1999. PMID: 10037184

7

Recent developments in breast cancer therapy.

Hortobagyi GN, Hung MC, Buzdar AU. Hortobagyi GN, et al. Semin Oncol. 1999 Aug;26(4 Suppl 12):11-20. Semin Oncol. 1999. PMID: 10482190 Review.

8

Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.

Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL 3rd, Bast R, Hortobagyi GN. Ibrahim NK, et al. Among authors: hortobagyi gn. Cancer. 1999 Oct 1;86(7):1251-7. doi: 10.1002/(sici)1097-0142(19991001)86:7<1251::aid-cncr21>3.0.co;2-f. Cancer. 1999. PMID: 10506711 Clinical Trial.

9

Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.

Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Pusztai L, et al. Among authors: hortobagyi gn. Cancer Treat Rev. 1999 Oct;25(5):271-7. doi: 10.1053/ctrv.1999.0132. Cancer Treat Rev. 1999. PMID: 10544071 Review.

10

Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients.

Lenert JT, Vlastos G, Mirza NQ, Winchester DJ, Binkley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Strom E, Buzdar AU, Hortobagyi GN, Singletary SE. Lenert JT, et al. Among authors: hortobagyi gn. Ann Surg Oncol. 1999 Dec;6(8):762-7. doi: 10.1007/s10434-999-0762-4. Ann Surg Oncol. 1999. PMID: 10622504 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,108 results

Search Page

Filters